The Hill (6/1, Choi) reports U.S. “consumers are overpaying billions for generic drugs due to the cost being driven up by” pharmacy benefit managers (PBMs), according to a reportby the University of Southern California. The report said, “Commercial tactics such as spread pricing, copay clawbacks and formularies that advantage branded drugs over less expensive generics have funneled the savings from low-cost generics into intermediaries’ pockets, rather than the pockets of patients.”
Related Links:
— “Industry middlemen driving up prices of generic drug prescriptions as much as 20 percent: research “Joseph Choi, The Hill, June 1, 2022